E-drug: Re: New leadership in WHO (8)
----------------------------------------------------------
I've been interested in the e-drug correspondence on WHO in general
and the appointment of Dr Scholtz in particular - and I share Mark
Raimaker's frustration at the tone of some of the comments
made on this site. But ultimately I think the dialogue is futile for all
kinds of reasons - notably these two:
[a] there is an obvious reason to be concerned about any appointment from
the heart of the pharmaceutical industry. So far as one can possibly tell,
this appointment had a great deal less to do with MS's experience in
this field, than with the state of WHO's finances, and its growing
dependence on 'extra-budgetary funds'. But beyond this:
[b] what matters is what MS does rather than where he comes from.
One can only speculate about the former and wait and see on the latter.
I've written a bit about the question of WHO dependence on industry
funding (and there's some relevant correspondence arising from it)
on The Antidepressant Web site. See:
http://www.socialaudit.org.uk/5104WHO.htm
Charles Medawar
Social Audit Ltd
PO Box 111
London NW1 8XG
socialaudit@gn.apc.org
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.